ESH AL 2018 | Clinical trials investigating venetoclax combinations for AML
Andrew Wei
• 4 May 2018
Andrew Wei, MBBS, PhD, FRACP, FRCPA, from Monash University, Melbourne, Australia, discusses the early trials that are currently underway to evaluate the efficacy of the BH3 mimetic drug, venetoclax, in combination with intensive chemotherapy, MDM2 inhibitors and MEK inhibitors for the management of acute myeloid leukemia (AML). Dr Wei also explains how research into venetoclax has shifted, with a focus on the molecular characteristics of the patients that have received the drug. This interview was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.
